Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications

Cancer Letters

Volumn 341, Issue 2, 2013, Pages 111-126

  Rydzanicz, Małgorzata ^a   Wrzesiński, Tomasz ^a   Bluyssen, Hans A R ^a   Wesoły, Joanna ^a  

^a ADAM MICKIEWICZ UNIVERSITY   (Poland)

Author keywords

Chromosomal aberrations; Clear cell renal cell carcinoma; DNA methylation; Gene expression; Large scale sequencing; MiRNA

Indexed keywords

AXITINIB; BEVACIZUMAB; DNA; HYPOXIA INDUCIBLE FACTOR; MESSENGER RNA; MICRORNA; PAZOPANIB; SORAFENIB; SUNITINIB; VON HIPPEL LINDAU PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER GENETICS; CANCER PROGNOSIS; CARCINOGENESIS; CHROMOSOME ABERRATION; DNA METHYLATION; DNA SEQUENCE; DRUG EFFICACY; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HETEROZYGOSITY LOSS; HUMAN; KIDNEY CARCINOMA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TREATMENT RESPONSE; CARCINOMA, RENAL CELL; EARLY DIAGNOSIS; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; KIDNEY NEOPLASMS; PROCEDURES; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

CARCINOMA, RENAL CELL; EARLY DIAGNOSIS; EPIGENOMICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84887184397     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.006     Document Type: Review

References (193)

1. Aron M., Nguyen M.M., Stein R.J., Gill I.S. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur. Urol. 2008, 54:133-140.
2. Cohen H.T., McGovern F.J. Renal-cell carcinoma. N. Engl. J. Med. 2005, 353:2477-2490.
3. Campbell D., Walker R., Mathew T., Craig J. Commentary on "Influence of industry on renal guideline development". Clin. J. Am. Soc. Nephrol. 2007, 2:211.
4. Lam J.S., Klatte T., Kim H.L., Patard J.J., Breda A., Zisman A., Pantuck A.J., Figlin R.A. Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit. Rev. Oncol. Hematol. 2008, 65:235-262.
5. Drucker B.J. Renal cell carcinoma: current status and future prospects. Cancer Treat. Rev. 2005, 31:536-545.
6. McDermott D.F., Regan M.M., Clark J.I., Flaherty L.E., Weiss G.R., Logan T.F., Kirkwood J.M., Gordon M.S., Sosman J.A., Ernstoff M.S., Tretter C.P., Urba W.J., Smith J.W., Margolin K.A., Mier J.W., Gollob J.A., Dutcher J.P., Atkins M.B. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2005, 23:133-141.
7. Belldegrun A.S., Klatte T., Shuch B., LaRochelle J.C., Miller D.C., Said J.W., Riggs S.B., Zomorodian N., Kabbinavar F.F., Dekernion J.B., Pantuck A.J. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008, 113:2457-2463.
8. Thomas R.K., Baker A.C., Debiasi R.M., Winckler W., Laframboise T., Lin W.M., Wang M., Feng W., Zander T., MacConaill L., Lee J.C., Nicoletti R., Hatton C., Goyette M., Girard L., Majmudar K., Ziaugra L., Wong K.K., Gabriel S., Beroukhim R., Peyton M., Barretina J., Dutt A., Emery C., Greulich H., Shah K., Sasaki H., Gazdar A., Minna J., Armstrong S.A., Mellinghoff I.K., Hodi F.S., Dranoff G., Mischel P.S., Cloughesy T.F., Nelson S.F., Liau L.M., Mertz K., Rubin M.A., Moch H., Loda M., Catalona W., Fletcher J., Signoretti S., Kaye F., Anderson K.C., Demetri G.D., Dummer R., Wagner S., Herlyn M., Sellers W.R., Meyerson M., Garraway L.A. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 2007, 39:347-351.
9. Meyerson M., Gabriel S., Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 2010, 11:685-696.
10. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., Mc Henry K.T., Pinchback R.M., Ligon A.H., Cho Y.J., Haery L., Greulich H., Reich M., Winckler W., Lawrence M.S., Weir B.A., Tanaka K.E., Chiang D.Y., Bass A.J., Loo A., Hoffman C., Prensner J., Liefeld T., Gao Q., Yecies D., Signoretti S., Maher E., Kaye F.J., Sasaki H., Tepper J.E., Fletcher J.A., Tabernero J., Baselga J., Tsao M.S., Demichelis F., Rubin M.A., Janne P.A., Daly M.J., Nucera C., Levine R.L., Ebert B.L., Gabriel S., Rustgi A.K., Antonescu C.R., Ladanyi M., Letai A., Garraway L.A., Loda M., Beer D.G., True L.D., Okamoto A., Pomeroy S.L., Singer S., Golub T.R., Lander E.S., Getz G., Sellers W.R., Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
11. Lizardi P.M., Forloni M., Wajapeyee N. Genome-wide approaches for cancer gene discovery. Trends Biotechnol. 2011.
12. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17:330-339.
13. Arai E., Kanai Y. Genetic and epigenetic alterations during renal carcinogenesis. Int. J. Clin. Exp. Pathol. 2011, 4:58-73.
14. Beroukhim R., Brunet J.P., Di Napoli A., Mertz K.D., Seeley A., Pires M.M., Linhart D., Worrell R.A., Moch H., Rubin M.A., Sellers W.R., Meyerson M., Linehan W.M., Kaelin W.G., Signoretti S. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009, 69:4674-4681.
15. Weng L., Wu X., Gao H., Mu B., Li X., Wang J.H., Guo C., Jin J.M., Chen Z., Covarrubias M., Yuan Y.C., Weiss L.M., Wu H. MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J. Pathol. 2010, 222:41-51.
16. Oosterwijk E., Rathmell W.K., Junker K., Brannon A.R., Pouliot F., Finley D.S., Mulders P.F., Kirkali Z., Uemura H., Belldegrun A. Basic research in kidney cancer. Eur. Urol. 2011, 60:622-633.
17. Nickerson M.L., Jaeger E., Shi Y., Durocher J.A., Mahurkar S., Zaridze D., Matveev V., Janout V., Kollarova H., Bencko V., Navratilova M., Szeszenia-Dabrowska N., Mates D., Mukeria A., Holcatova I., Schmidt L.S., Toro J.R., Karami S., Hung R., Gerard G.F., Linehan W.M., Merino M., Zbar B., Boffetta P., Brennan P., Rothman N., Chow W.H., Waldman F.M., Moore L.E. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 2008, 14:4726-4734.
18. Nyhan M.J., O'Sullivan G.C., McKenna S.L. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem. Soc. Trans. 2008, 36:472-478.
19. Baldewijns M.M., van Vlodrop I.J., Schouten L.J., Soetekouw P.M., de Bruine A.P., van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim. Biophys. Acta 2008, 1785:133-155.
20. Patard J.J., Rioux-Leclercq N., Masson D., Zerrouki S., Jouan F., Collet N., Dubourg C., Lobel B., Denis M., Fergelot P. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br. J. Cancer 2009, 101:1417-1424.
21. Nordstrom-O'Brien M., van der Luijt R.B., van Rooijen E., van den Ouweland A.M., Majoor-Krakauer D.F., Lolkema M.P., van Brussel A., Voest E.E., Giles R.H. Genetic analysis of von Hippel-Lindau disease. Hum. Mutat. 2010, 31:521-537.
22. Banks R.E., Tirukonda P., Taylor C., Hornigold N., Astuti D., Cohen D., Maher E.R., Stanley A.J., Harnden P., Joyce A., Knowles M., Selby P.J. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006, 66:2000-2011.
23. Moore L.E., Nickerson M.L., Brennan P., Toro J.R., Jaeger E., Rinsky J., Han S.S., Zaridze D., Matveev V., Janout V., Kollarova H., Bencko V., Navratilova M., Szeszenia-Dabrowska N., Mates D., Schmidt L.S., Lenz P., Karami S., Linehan W.M., Merino M., Chanock S., Boffetta P., Chow W.H., Waldman F.M., Rothman N. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet. 2011, 7:e1002312.
24. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., Pavletich N., Chau V., Kaelin W.G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2000, 2:423-427.
25. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
26. Gossage L., Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat. Rev. Clin. Oncol. 2010, 7:277-288.
27. Haase V.H. The VHL tumor suppressor: master regulator of HIF. Curr. Pharm. Des. 2009, 15:3895-3903.
28. Bluyssen H.A., Lolkema M.P., van Beest M., Boone M., Snijckers C.M., Los M., Gebbink M.F., Braam B., Holstege F.C., Giles R.H., Voest E.E. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett. 2004, 556:137-142.
29. Kaelin W.G. Von Hippel-Lindau disease. Annu. Rev. Pathol. 2007, 2:145-173.
30. Frew I.J., Krek W. Multitasking by pVHL in tumour suppression. Curr. Opin. Cell Biol. 2007, 19:685-690.
31. Yang H., Minamishima Y.A., Yan Q., Schlisio S., Ebert B.L., Zhang X., Zhang L., Kim W.Y., Olumi A.F., Kaelin W.G. PVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol. Cell 2007, 28:15-27.
32. Breen E.C. VEGF in biological control. J. Cell. Biochem. 2007, 102:1358-1367.
33. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9:327-337.
34. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
35. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug. Discov. 2004, 3:391-400.
36. Huang S., Houghton P.J. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Investig. Drugs 2002, 3:295-304.
37. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356:115-124.
38. Vogelzang N.J. Another step toward the cure of metastatic renal cell carcinoma?. J. Clin. Oncol. 2010, 28:5017-5019.
39. Singer E.A., Gupta G.N., Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr. Opin. Oncol. 2011, 24:284-290.
40. Coppin C., Kollmannsberger C., Le L., Porzsolt F., Wilt T.J. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2012, 108:1556-1563.
41. Eisengart L.J., Macvicar G.R., Yang X.J. Predictors of response to targeted therapy in renal cell carcinoma. Arch. Pathol. Lab. Med. 2012, 136:490-495.
42. Zhao H., Ljungberg B., Grankvist K., Rasmuson T., Tibshirani R., Brooks J.D. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 2006, 3:e13.
43. Gordan J.D., Lal P., Dondeti V.R., Letrero R., Parekh K.N., Oquendo C.E., Greenberg R.A., Flaherty K.T., Rathmell W.K., Keith B., Simon M.C., Nathanson K.L. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008, 14:435-446.
44. Brannon A.R., Reddy A., Seiler M., Arreola A., Moore D.T., Pruthi R.S., Wallen E.M., Nielsen M.E., Liu H., Nathanson K.L., Ljungberg B., Zhao H., Brooks J.D., Ganesan S., Bhanot G., Rathmell W.K. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010, 1:152-163.
45. Sanjmyatav J., Steiner T., Wunderlich H., Diegmann J., Gajda M., Junker K. A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma. J. Urol. 2011, 186:289-294.
46. Chen M., Ye Y., Yang H., Tamboli P., Matin S., Tannir N.M., Wood C.G., Gu J., Wu X. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int. J. Cancer 2009, 125:2342-2348.
47. Moore L.E., Jaeger E., Nickerson M.L., Brennan P., De Vries S., Roy R., Toro J., Li H., Karami S., Lenz P., Zaridze D., Janout V., Bencko V., Navratilova M., Szeszenia-Dabrowska N., Mates D., Linehan W.M., Merino M., Simko J., Pfeiffer R., Boffetta P., Hewitt S., Rothman N., Chow W.H., Waldman F.M. Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation. Oncogenesis 2012, 1:e14.
48. Klatte T., Rao P.N., de Martino M., LaRochelle J., Shuch B., Zomorodian N., Said J., Kabbinavar F.F., Belldegrun A.S., Pantuck A.J. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J. Clin. Oncol. 2009, 27:746-753.
49. Shuib S., Wei W., Sur H., Morris M.R., McMullan D., Rattenberry E., Meyer E., Maxwell P.H., Kishida T., Yao M., Latif F., Maher E.R. Copy number profiling in von Hippel-Lindau disease renal cell carcinoma. Genes Chromosom. Cancer 2011, 50:479-488.
50. Pei J., Feder M.M., Al-Saleem T., Liu Z., Liu A., Hudes G.R., Uzzo R.G., Testa J.R. Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma. Genes Chromosom. Cancer 2010, 49:610-619.
51. Bhat S. Role of surgery in advanced/metastatic renal cell carcinoma. Indian J. Urol. 2010, 26:167-176.
52. Dondeti V.R., Wubbenhorst B., Lal P., Gordan J.D., D'Andrea K., Attiyeh E.F., Simon M.C., Nathanson K.L. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res. 2012, 72:112-121.
53. D. Matsuda, S.K. Khoo, A. Massie, M. Iwamura, J. Chen, D. Petillo, B. Wondergem, M. Avallone, S.J. Kloostra, M.H. Tan, J. Koeman, Z. Zhang, R.J. Kahnoski, G. French Kidney Cancer Study, S. Baba, B.T. Teh, Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC, Cancer Lett. 272 (2008) 260-267.
54. Toma M.I., Grosser M., Herr A., Aust D.E., Meye A., Hoefling C., Fuessel S., Wuttig D., Wirth M.P., Baretton G.B. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia 2008, 10:634-642.
55. Soares M.J., Pinto M., Henrique R., Vieira J., Cerveira N., Peixoto A., Martins A.T., Oliveira J., Jeronimo C., Teixeira M.R. CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. Modern Pathol.: Off. J. US Can. Acad. Path., Inc. 2009, 22:744-752.
56. Girgis A.H., Iakovlev V.V., Beheshti B., Bayani J., Squire J.A., Bui A., Mankaruos M., Youssef Y., Khalil B., Khella H., Pasic M., Yousef G.M. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res. 2012, 72:5273-5284.
57. Shen C., Beroukhim R., Schumacher S.E., Zhou J., Chang M., Signoretti S., Kaelin W.G. Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. Cancer Discov. 2011, 1:222-235.
58. Yoshimoto T., Matsuura K., Karnan S., Tagawa H., Nakada C., Tanigawa M., Tsukamoto Y., Uchida T., Kashima K., Akizuki S., Takeuchi I., Sato F., Mimata H., Seto M., Moriyama M. High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. J. Pathol. 2007, 213:392-401.
59. Arai E., Ushijima S., Tsuda H., Fujimoto H., Hosoda F., Shibata T., Kondo T., Imoto I., Inazawa J., Hirohashi S., Kanai Y. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome. Clin. Cancer Res. 2008, 14:5531-5539.
60. Kroeger N., Klatte T., Chamie K., Rao P.N., Birkhauser F.D., Sonn G.A., Riss J., Kabbinavar F.F., Belldegrun A.S., Pantuck A.J. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. Cancer 2013, 119:1547-1554.
61. La Rochelle J., Klatte T., Dastane A., Rao N., Seligson D., Said J., Shuch B., Zomorodian N., Kabbinavar F., Belldegrun A., Pantuck A.J. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer 2010, 116:4696-4702.
62. Sanjmyatav J., Junker K., Matthes S., Muehr M., Sava D., Sternal M., Wessendorf S., Kreuz M., Gajda M., Wunderlich H., Schwaenen C. Identification of genomic alterations associated with metastasis and cancer specific survival in clear cell renal cell carcinoma. J. Urol. 2011, 186:2078-2083.
63. van Haaften G., Dalgliesh G.L., Davies H., Chen L., Bignell G., Greenman C., Edkins S., Hardy C., O'Meara S., Teague J., Butler A., Hinton J., Latimer C., Andrews J., Barthorpe S., Beare D., Buck G., Campbell P.J., Cole J., Forbes S., Jia M., Jones D., Kok C.Y., Leroy C., Lin M.L., McBride D.J., Maddison M., Maquire S., McLay K., Menzies A., Mironenko T., Mulderrig L., Mudie L., Pleasance E., Shepherd R., Smith R., Stebbings L., Stephens P., Tang G., Tarpey P.S., Turner R., Turrell K., Varian J., West S., Widaa S., Wray P., Collins V.P., Ichimura K., Law S., Wong J., Yuen S.T., Leung S.Y., Tonon G., DePinho R.A., Tai Y.T., Anderson K.C., Kahnoski R.J., Massie A., Khoo S.K., Teh B.T., Stratton M.R., Futreal P.A. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 2009, 41:521-523.
64. Wang J.K., Tsai M.C., Poulin G., Adler A.S., Chen S., Liu H., Shi Y., Chang H.Y. The histone demethylase UTX enables RB-dependent cell fate control. Genes Dev. 2010, 24:327-332.
65. Herz H.M., Madden L.D., Chen Z., Bolduc C., Buff E., Gupta R., Davuluri R., Shilatifard A., Hariharan I.K., Bergmann A. The H3K27me3 demethylase dUTX is a suppressor of Notch- and Rb-dependent tumors in Drosophila. Mol. Cell. Biol. 2010, 30:2485-2497.
66. Dalgliesh G.L., Furge K., Greenman C., Chen L., Bignell G., Butler A., Davies H., Edkins S., Hardy C., Latimer C., Teague J., Andrews J., Barthorpe S., Beare D., Buck G., Campbell P.J., Forbes S., Jia M., Jones D., Knott H., Kok C.Y., Lau K.W., Leroy C., Lin M.L., McBride D.J., Maddison M., Maguire S., McLay K., Menzies A., Mironenko T., Mulderrig L., Mudie L., O'Meara S., Pleasance E., Rajasingham A., Shepherd R., Smith R., Stebbings L., Stephens P., Tang G., Tarpey P.S., Turrell K., Dykema K.J., Khoo S.K., Petillo D., Wondergem B., Anema J., Kahnoski R.J., Teh B.T., Stratton M.R., Futreal P.A. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
67. Zhou L., Hanemann C.O. Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett. 2012, 586:1403-1408.
68. Sun X.J., Wei J., Wu X.Y., Hu M., Wang L., Wang H.H., Zhang Q.H., Chen S.J., Huang Q.H., Chen Z. Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. J. Biol. Chem. 2005, 280:35261-35271.
69. Iwase S., Lan F., Bayliss P., de la Torre-Ubieta L., Huarte M., Qi H.H., Whetstine J.R., Bonni A., Roberts T.M., Shi Y. The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell 2007, 128:1077-1088.
70. Milne T.A., Briggs S.D., Brock H.W., Martin M.E., Gibbs D., Allis C.D., Hess J.L. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol. Cell 2002, 10:1107-1117.
71. Duns G., van den Berg E., van Duivenbode I., Osinga J., Hollema H., Hofstra R.M., Kok K. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 2010, 70:4287-4291.
72. J.M. Krill-Burger, M.A. Lyons, L.A. Kelly, C.M. Sciulli, P. Petrosko, U.R. Chandran, M.D. Kubal, S.I. Bastacky, A.V. Parwani, R. Dhir, W.A. Laframboise, Renal cell neoplasms contain shared tumor type-specific copy number variations, Am. J. Pathol. (2012).
73. Guo G., Gui Y., Gao S., Tang A., Hu X., Huang Y., Jia W., Li Z., He M., Sun L., Song P., Sun X., Zhao X., Yang S., Liang C., Wan S., Zhou F., Chen C., Zhu J., Li X., Jian M., Zhou L., Ye R., Huang P., Chen J., Jiang T., Liu X., Wang Y., Zou J., Jiang Z., Wu R., Wu S., Fan F., Zhang Z., Liu L., Yang R., Wu H., Yin W., Liu Y., Peng H., Jiang B., Feng Q., Li C., Xie J., Lu J., Kristiansen K., Li Y., Zhang X., Li S., Wang J., Yang H., Cai Z. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat. Genet. 2011, 44:17-19.
74. Wang L., Tsutsumi S., Kawaguchi T., Nagasaki K., Tatsuno K., Yamamoto S., Sang F., Sonoda K., Sugawara M., Saiura A., Hirono S., Yamaue H., Miki Y., Isomura M., Totoki Y., Nagae G., Isagawa T., Ueda H., Murayama-Hosokawa S., Shibata T., Sakamoto H., Kanai Y., Kaneda A., Noda T., Aburatani H. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res. 2012, 22:208-219.
75. Niu X., Zhang T., Liao L., Zhou L., Lindner D.J., Zhou M., Rini B., Yan Q., Yang H. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 2012, 31:776-786.
76. Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J., Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M., Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L., Stebbings L., Largaespada D.A., Wessels L.F., Richard S., Kahnoski R.J., Anema J., Tuveson D.A., Perez-Mancera P.A., Mustonen V., Fischer A., Adams D.J., Rust A., Chan-on W., Subimerb C., Dykema K., Furge K., Campbell P.J., Teh B.T., Stratton M.R., Futreal P.A. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
77. Burrows A.E., Smogorzewska A., Elledge S.J. Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc. Natl. Acad. Sci. USA 2010, 107:14280-14285.
78. Xia W., Nagase S., Montia A.G., Kalachikov S.M., Keniry M., Su T., Memeo L., Hibshoosh H., Parsons R. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res. 2008, 68:1667-1674.
79. Xue Y., Canman J.C., Lee C.S., Nie Z., Yang D., Moreno G.T., Young M.K., Salmon E.D., Wang W. The human SWI/SNF-B chromatin-remodeling complex is related to yeast rsc and localizes at kinetochores of mitotic chromosomes. Proc. Natl. Acad. Sci. USA 2000, 97:13015-13020.
80. Vries R.G., Bezrookove V., Zuijderduijn L.M., Kia S.K., Houweling A., Oruetxebarria I., Raap A.K., Verrijzer C.P. Cancer-associated mutations in chromatin remodeler hSNF5 promote chromosomal instability by compromising the mitotic checkpoint. Genes Dev. 2005, 19:665-670.
81. Duns G., Hofstra R.M., Sietzema J.G., Hollema H., van Duivenbode I., Kuik A., Giezen C., Jan O., Bergsma J.J., Bijnen H., van der Vlies P., van den Berg E., Kok K. Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum. Mutat. 2012.
82. Pena-Llopis S., Vega-Rubin-de-Celis S., Liao A., Leng N., Pavia-Jimenez A., Wang S., Yamasaki T., Zhrebker L., Sivanand S., Spence P., Kinch L., Hambuch T., Jain S., Lotan Y., Margulis V., Sagalowsky A.I., Summerour P.B., Kabbani W., Wong S.W., Grishin N., Laurent M., Xie X.J., Haudenschild C.D., Ross M.T., Bentley D.R., Kapur P., Brugarolas J. BAP1 loss defines a new class of renal cell carcinoma. Nat. Genet. 2012, 44:751-759.
83. R. Pawlowski, S.M. Muhl, T. Sulser, W. Krek, H. Moch, P. Schraml, Loss of PBRM1 expression is associated with renal cell carcinoma progression, Int. J. Cancer (2012).
84. Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R., Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166.
85. H. Yu, N. Mashtalir, S. Daou, I. Hammond-Martel, J. Ross, G. Sui, G.W. Hart, F.J. Rauscher, 3rd, E. Drobetsky, E. Milot, Y. Shi, B. Affar, et al., The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression, Mol. Cell Biol. 30 (2010) 5071-5085.
86. Harbour J.W., Onken M.D., Roberson E.D., Duan S., Cao L., Worley L.A., Council M.L., Matatall K.A., Helms C., Bowcock A.M. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330:1410-1413.
87. Njauw C.N., Kim I., Piris A., Gabree M., Taylor M., Lane A.M., Deangelis M.M., Gragoudas E., Duncan L.M., Tsao H. Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families. PLoS ONE 2012, 7:e35295.
88. Inoki K., Li Y., Xu T., Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 17:1829-1834.
89. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
90. Zhang G., Kernan K.A., Thomas A., Collins S., Song Y., Li L., Zhu W., Leboeuf R.C., Eddy A.A. A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis. J. Biol. Chem. 2009, 284:29050-29064.
91. Shankar J., Messenberg A., Chan J., Underhill T.M., Foster L.J., Nabi I.R. Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res. 2010, 70:3780-3790.
92. Pan T., Li X., Jankovic J. The association between Parkinson's disease and melanoma. Int. J. Cancer 2011, 128:2251-2260.
93. Inzelberg R., Cohen O.S., Aharon-Peretz J., Schlesinger I., Gershoni-Baruch R., Djaldetti R., Nitsan Z., Ephraty L., Tunkel O., Kozlova E., Inzelberg L., Kaplan N., Fixler Mehr T., Mory A., Dagan E., Schechtman E., Friedman E., Hassin-Baer S. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology 2012, 78:781-786.
94. Xu X., Hou Y., Yin X., Bao L., Tang A., Song L., Li F., Tsang S., Wu K., Wu H., He W., Zeng L., Xing M., Wu R., Jiang H., Liu X., Cao D., Guo G., Hu X., Gui Y., Li Z., Xie W., Sun X., Shi M., Cai Z., Wang B., Zhong M., Li J., Lu Z., Gu N., Zhang X., Goodman L., Bolund L., Wang J., Yang H., Kristiansen K., Dean M., Li Y. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012, 148:886-895.
95. Nakamura T., Hillova J., Mariage-Samson R., Onno M., Huebner K., Cannizzaro L.A., Boghosian-Sell L., Croce C.M., Hill M. A novel transcriptional unit of the tre oncogene widely expressed in human cancer cells. Oncogene 1992, 7:733-741.
96. Ye Y., Pringle L.M., Lau A.W., Riquelme D.N., Wang H., Jiang T., Lev D., Welman A., Blobel G.A., Oliveira A.M., Chou M.M. TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappaB. Oncogene 2010, 29:3619-3629.
97. Rueckert C., Haucke V. The oncogenic TBC domain protein USP6/TRE17 regulates cell migration and cytokinesis. Biol. Cell 2012, 104:22-33.
98. A.A. Hakimi, Y.B. Chen, J. Wren, M. Gonen, O. Abdel-Wahab, A. Heguy, H. Liu, S. Takeda, S.K. Tickoo, V.E. Reuter, M.H. Voss, R.J. Motzer, J.A. Coleman, E.H. Cheng, P. Russo, J.J. Hsieh, Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma, Eur. Urol. (2012).
99. Tun H.W., Marlow L.A., von Roemeling C.A., Cooper S.J., Kreinest P., Wu K., Luxon B.A., Sinha M., Anastasiadis P.Z., Copland J.A. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS ONE 2010, 5:e10696.
100. Zhou L., Chen J., Li Z., Li X., Hu X., Huang Y., Zhao X., Liang C., Wang Y., Sun L., Shi M., Xu X., Shen F., Chen M., Han Z., Peng Z., Zhai Q., Zhang Z., Yang R., Ye J., Guan Z., Yang H., Gui Y., Wang J., Cai Z., Zhang X. Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS ONE 2010, 5:e15224.
101. Piekielko-Witkowska A., Wiszomirska H., Wojcicka A., Poplawski P., Boguslawska J., Tanski Z., Nauman A. Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors. PLoS ONE 2010, 5:e13690.
102. Tang S.W., Lin J.Y. Full-length enrich c-DNA libraries-clear cell-renal cell carcinoma. J. Oncol. 2012, 2012:680796.
103. Yao M., Huang Y., Shioi K., Hattori K., Murakami T., Sano F., Baba M., Kondo K., Nakaigawa N., Kishida T., Nagashima Y., Yamada-Okabe H., Kubota Y. A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma. Int. J. Cancer 2008, 123:1126-1132.
104. Lane B.R., Li J., Zhou M., Babineau D., Faber P., Novick A.C., Williams B.R. Differential expression in clear cell renal cell carcinoma identified by gene expression profiling. J. Urol. 2009, 181:849-860.
105. Maruschke M., Reuter D., Koczan D., Hakenberg O.W., Thiesen H.J. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management. BJU Int. 2011, 108:E29-E35.
106. Busse A., Asemissen A., Nonnenmacher A., Ochsenreither S., Fusi A., Braun F., Stather D., Schmittel A., Miller K., Thiel E., Keilholz U. Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-beta1 mRNA expression in peripheral blood mononuclear cells. J. Immunother. 2011, 34:113-119.
107. Takacova M., Bartosova M., Skvarkova L., Zatovicova M., Vidlickova I., Csaderova L., Barathova M., Breza J., Bujdak P., Pastorek J., Breza J., Pastorekova S. Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma. Oncol. Lett. 2013, 5:191-197.
108. Brannon A.R., Haake S.M., Hacker K.E., Pruthi R.S., Wallen E.M., Nielsen M.E., Rathmell W.K. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur. Urol. 2012, 61:258-268.
109. S.R. Williamson, J.N. Eble, L. Cheng, D.J. Grignon, Re: A. Rose Brannon, Scott M. Haake, Kathryn E. Hacker, et al. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur. Urol. 61(2012) 258-68 (Eur. Urol. (2012)).
110. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
111. Oulas A., Karathanasis N., Louloupi A., Poirazi P. Finding cancer-associated miRNAs: methods and tools. Mol. Biotechnol. 2011, 49:97-107.
112. Jung M., Mollenkopf H.J., Grimm C., Wagner I., Albrecht M., Waller T., Pilarsky C., Johannsen M., Stephan C., Lehrach H., Nietfeld W., Rudel T., Jung K., Kristiansen G. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J. Cell Mol. Med. 2009, 13:3918-3928.
113. Juan D., Alexe G., Antes T., Liu H., Madabhushi A., Delisi C., Ganesan S., Bhanot G., Liou L.S. Identification of a microRNA panel for clear-cell kidney cancer. Urology 2010, 75:835-841.
114. White N.M., Bao T.T., Grigull J., Youssef Y.M., Girgis A., Diamandis M., Fatoohi E., Metias M., Honey R.J., Stewart R., Pace K.T., Bjarnason G.A., Yousef G.M. MiRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J. Urol. 2011, 186:1077-1083.
115. Osanto S., Qin Y., Buermans H.P., Berkers J., Lerut E., Goeman J.J., van Poppel H. Genome-wide MicroRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS ONE 2012, 7:e38298.
116. Petillo D., Kort E.J., Anema J., Furge K.A., Yang X.J., Teh B.T. MicroRNA profiling of human kidney cancer subtypes. Int. J. Oncol. 2009, 35:109-114.
117. Fridman E., Dotan Z., Barshack I., David M.B., Dov A., Tabak S., Zion O., Benjamin S., Benjamin H., Kuker H., Avivi C., Rosenblatt K., Polak-Charcon S., Ramon J., Rosenfeld N., Spector Y. Accurate molecular classification of renal tumors using microRNA expression. J. Mol. Diagn. 2010, 12:687-696.
118. Youssef Y.M., White N.M., Grigull J., Krizova A., Samy C., Mejia-Guerrero S., Evans A., Yousef G.M. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur. Urol. 2011, 59:721-730.
119. Samplaski M.K., Zhou M., Lane B.R., Herts B., Campbell S.C. Renal mass sampling: an enlightened perspective. Int. J. Urol. 2011, 18:5-19.
120. Heinzelmann J., Henning B., Sanjmyatav J., Posorski N., Steiner T., Wunderlich H., Gajda M.R., Junker K. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J. Urol. 2011, 29:367-373.
121. White N.M., Khella H.W., Grigull J., Adzovic S., Youssef Y.M., Honey R.J., Stewart R., Pace K.T., Bjarnason G.A., Jewett M.A., Evans A.J., Gabril M., Yousef G.M. MiRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br. J. Cancer 2011, 105:1741-1749.
122. Wotschofsky Z., Liep J., Meyer H.A., Jung M., Wagner I., Disch A.C., Schaser K.D., Melcher I., Kilic E., Busch J., Weikert S., Miller K., Erbersdobler A., Mollenkopf H.J., Jung K. Identification of metastamirs as metastasis-associated MicroRNAs in clear cell renal cell carcinomas. Int. J. Biol. Sci. 2012, 8:1363-1374.
123. Pan X., Wang Z.X., Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol. Ther. 2011, 10:1224-1232.
124. Wang H., Tan G., Dong L., Cheng L., Li K., Wang Z., Luo H. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS ONE 2012, 7:e34210.
125. Bitarte N., Bandres E., Boni V., Zarate R., Rodriguez J., Gonzalez-Huarriz M., Lopez I., Javier Sola J., Alonso M.M., Fortes P., Garcia-Foncillas J. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem cells 2011, 29:1661-1671.
126. A. Zhao, G. Li, M. Peoc'h, C. Genin, M. Gigante, Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma, Exp. Mol. Pathol. (2012).
127. Redova M., Poprach A., Nekvindova J., Iliev R., Radova L., Lakomy R., Svoboda M., Vyzula R., Slaby O. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Transl. Med. 2012, 10:55.
128. Wulfken L.M., Moritz R., Ohlmann C., Holdenrieder S., Jung V., Becker F., Herrmann E., Walgenbach-Brunagel G., von Ruecker A., Muller S.C., Ellinger J. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS ONE 2011, 6:e25787.
129. Zhai Q., Zhou L., Zhao C., Wan J., Yu Z., Guo X., Qin J., Chen J., Lu R. Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem. Biophys. Res. Commun. 2012, 419:621-626.
130. von Brandenstein M., Pandarakalam J.J., Kroon L., Loeser H., Herden J., Braun G., Wendland K., Dienes H.P., Engelmann U., Fries J.W. MicroRNA 15a, inversely correlated to PKCalpha, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am. J. Pathol. 2012, 180:1787-1797.
131. Henry J.C., Azevedo-Pouly A.C., Schmittgen T.D. MicroRNA replacement therapy for cancer. Pharm. Res. 2011, 28:3030-3042.
132. Ebert M.S., Sharp P.A. MicroRNA sponges: progress and possibilities. RNA 2010, 16:2043-2050.
133. Hsieh J., Gage F.H. Epigenetic control of neural stem cell fate. Curr. Opin. Genet. Dev. 2004, 14:461-469.
134. Robertson K.D. DNA methylation and human disease. Nat. Rev. Genet. 2005, 6:597-610.
135. Sandoval J., Esteller M. Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev. 2012, 22:50-55.
136. Morris M.R., Maher E.R. Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome. Med. 2010, 2:59.
137. Costa V.L., Henrique R., Danielsen S.A., Eknaes M., Patricio P., Morais A., Oliveira J., Lothe R.A., Teixeira M.R., Lind G.E., Jeronimo C. TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics 2011, 6:1120-1130.
138. McRonald F.E., Morris M.R., Gentle D., Winchester L., Baban D., Ragoussis J., Clarke N.W., Brown M.D., Kishida T., Yao M., Latif F., Maher E.R. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol. Cancer 2009, 8:31.
139. Morris M.R., Ricketts C., Gentle D., Abdulrahman M., Clarke N., Brown M., Kishida T., Yao M., Latif F., Maher E.R. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 2010, 29:2104-2117.
140. Morris M.R., Ricketts C.J., Gentle D., McRonald F., Carli N., Khalili H., Brown M., Kishida T., Yao M., Banks R.E., Clarke N., Latif F., Maher E.R. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 2011, 30:1390-1401.
141. Ricketts C.J., Morris M.R., Gentle D., Brown M., Wake N., Woodward E.R., Clarke N., Latif F., Maher E.R. Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics 2012, 7:278-290.
142. Arai E., Chiku S., Mori T., Gotoh M., Nakagawa T., Fujimoto H., Kanai Y. Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis 2012, 33:1487-1493.
143. de Martino M., Klatte T., Haitel A., Marberger M. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer 2012, 118:82-90.
144. Bennett K.L., Campbell R., Ganapathi S., Zhou M., Rini B., Ganapathi R., Neumann H.P., Eng C. Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes Chromosom. Cancer 2011, 50:654-661.
145. Liao L.M., Brennan P., van Bemmel D.M., Zaridze D., Matveev V., Janout V., Kollarova H., Bencko V., Navratilova M., Szeszenia-Dabrowska N., Mates D., Rothman N., Boffetta P., Chow W.H., Moore L.E. LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer. PLoS ONE 2011, 6:e27361.
146. Heyn H., Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat. Rev. Genet. 2012, 13:679-692.
147. Shang D., Liu Y., Xu X., Han T., Tian Y. 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-beta-catenin expression. Cancer Lett. 2011, 311:230-236.
148. Negrotto S., Hu Z., Alcazar O., Ng K.P., Triozzi P., Lindner D., Rini B., Saunthararajah Y. Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res. 2011, 71:1431-1441.
149. Guo G., Gui Y., Gao S., Tang A., Hu X., Huang Y., Jia W., Li Z., He M., Sun L., Song P., Sun X., Zhao X., Yang S., Liang C., Wan S., Zhou F., Chen C., Zhu J., Li X., Jian M., Zhou L., Ye R., Huang P., Chen J., Jiang T., Liu X., Wang Y., Zou J., Jiang Z., Wu R., Wu S., Fan F., Zhang Z., Liu L., Yang R., Wu H., Yin W., Liu Y., Peng H., Jiang B., Feng Q., Li C., Xie J., Lu J., Kristiansen K., Li Y., Zhang X., Li S., Wang J., Yang H., Cai Z. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat. Genet. 2012, 44:17-19.
150. Wu S., Wang Y., Sun L., Zhang Z., Jiang Z., Qin Z., Han H., Liu Z., Li X., Tang A., Gui Y., Cai Z., Zhou F. Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma. BMC Cancer 2011, 11:413.
151. J.J. Ma, L.M. Kong, C.G. Liao, X. Jiang, Y. Wang, T.Y. Bao, Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion, Med. Oncol. (2012).
152. Casagrande S., Ruf M., Rechsteiner M., Morra L., Brun-Schmid S., von Teichman A., Krek W., Schraml P., Moch H. The protein-tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma. J. Pathol. 2012.
153. M.I. Toma, D. Wuttig, S. Kaiser, A. Herr, T. Weber, S. Zastrow, R. Koch, M. Meinhardt, G.B. Baretton, M.P. Wirth, S. Fuessel, PARK2 and PACRG are commonly downregulated in clear-cell renal cell carcinoma and are associated with aggressive disease and poor clinical outcome, Genes Chromosom. Cancer (2012).
154. J.T. Lin, T.S. Tzai, C.Y. Liao, J.S. Wang, T.T. Wu, H.Y. Wang, C.H. Wu, C.C. Yu, P.J. Lu, WWOX Protein expression varies among RCC histotypes and downregulation of WWOX protein correlates with less-favorable prognosis in clear RCC, Ann. Surg. Oncol. (2012).
155. Tan W., Hildebrandt M.A., Pu X., Huang M., Lin J., Matin S.F., Tamboli P., Wood C.G., Wu X. Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes. J. Urol. 2011, 186:2071-2077.
156. Ren J., Li W., Yan L., Jiao W., Tian S., Li D., Tang Y., Gu G., Liu H., Xu Z. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival. Br. J. Cancer 2011, 105:1905-1911.
157. Hildebrandt M.A., Tan W., Tamboli P., Huang M., Ye Y., Lin J., Lee J.S., Wood C.G., Wu X. Kinome expression profiling identifies IKBKE as a predictor of overall survival in clear cell renal cell carcinoma patients. Carcinogenesis 2012, 33:799-803.
158. Wuttig D., Zastrow S., Fussel S., Toma M.I., Meinhardt M., Kalman K., Junker K., Sanjmyatav J., Boll K., Hackermuller J., Rolle A., Grimm M.O., Wirth M.P. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Int. J. Cancer 2012, 131:E693-E704.
159. Gahan J.C., Gosalbez M., Yates T., Young E.E., Escudero D.O., Chi A., Garcia-Roig M., Satyanarayana R., Soloway M.S., Bird V.G., Lokeshwar V.B. Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis. J. Urol. 2012, 187:827-833.
160. Ai Q., Ma X., Huang Q., Liu S., Shi T., Zhang C., Zhu M., Zhang Y., Wang B., Ni D., Li H., Zheng T., Zhang X. High-level expression of Notch1 increased the risk of metastasis in T1 stage clear cell renal cell carcinoma. PLoS ONE 2012, 7:e35022.
161. Deville J.L., Bartoli C., Berenguer C., Fernandez-Sauze S., Kaafarani I., Delfino C., Fina F., Salas S., Muracciole X., Mancini J., Lechevallier E., Martin P.M., Figarella-Branger D., Ouafik L., Daniel L. Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma. Int. J. Cancer 2009, 125:2307-2315.
162. Pu Y.S., Huang C.Y., Chen J.Y., Kang W.Y., Lin Y.C., Shiu Y.S., Chuang S.J., Yu H.J., Lai M.K., Tsai Y.C., Wu W.J., Hour T.C. Down-regulation of PKCzeta in renal cell carcinoma and its clinicopathological implications. J. Biomed. Sci. 2012, 19:39.
163. Masson D., Rioux-Leclercq N., Fergelot P., Jouan F., Mottier S., Theoleyre S., Bach-Ngohou K., Patard J.J., Denis M.G. Loss of expression of TIMP3 in clear cell renal cell carcinoma. Eur. J. Cancer 2010, 46:1430-1437.
164. Huang Y., Murakami T., Sano F., Kondo K., Nakaigawa N., Kishida T., Kubota Y., Nagashima Y., Yao M. Expression of aquaporin 1 in primary renal tumors: a prognostic indicator for clear-cell renal cell carcinoma. Eur. Urol. 2009, 56:690-698.
165. Lei Y., Geng Z., Guo-Jun W., He W., Jian-Lin Y. Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance. Mol. Cell. Biochem. 2010, 344:23-31.
166. Lee J.W., Park J.H., Suh J.H., Nam K.H., Choe J.Y., Jung H.Y., Chae J.Y., Moon K.C. Cyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma. Korean J. Pathol. 2012, 46:237-245.
167. Bot B.M., Eckel-Passow J.E., LeGrand S.N., Hilton T., Cheville J.C., Igel T., Parker A.S. Expression of endothelin 2 and localized clear cell renal cell carcinoma. Hum. Pathol. 2012, 43:843-849.
168. Xue Y.J., Xiao R.H., Long D.Z., Zou X.F., Wang X.N., Zhang G.X., Yuan Y.H., Wu G.Q., Yang J., Wu Y.T., Xu H., Liu F.L., Liu M. Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma. J. Transl. Med. 2012, 10:200.
169. Chen Y., Yusenko M.V., Kovacs G. Lack of KISS1R expression is associated with rapid progression of conventional renal cell carcinomas. J. Pathol. 2011, 223:46-53.
170. X.R. Wu, J.J. Sha, D.M. Liu, Y.H. Chen, G.L. Yang, J. Zhang, Y.Y. Chen, J.J. Bo, Y.R. Huang, High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma, Eur. J. Surg. Oncol. (2012).
171. Waalkes S., Atschekzei F., Kramer M.W., Hennenlotter J., Vetter G., Becker J.U., Stenzl A., Merseburger A.S., Schrader A.J., Kuczyk M.A., Serth J. Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer 2010, 10:503.
172. Ding Y., Huang D., Zhang Z., Smith J., Petillo D., Looyenga B.D., Feenstra K., Mackeigan J.P., Furge K.A., Teh B.T. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets. Cancer Res. 2011, 71:5225-5234.
173. B. Wondergem, Z. Zhang, D. Huang, C.K. Ong, J. Koeman, D. Van't Hof, D. Petillo, A. Ooi, J. Anema, B. Lane, R.J. Kahnoski, K.A. Furge, B.T. Teh, Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma, Cancer Res (2012).
174. Neal C.S., Michael M.Z., Rawlings L.H., Van der Hoek M.B., Gleadle J.M. The VHL-dependent regulation of microRNAs in renal cancer. BMC Med. 2010, 8:64.
175. Khella H.W., White N.M., Faragalla H., Gabril M., Boazak M., Dorian D., Khalil B., Antonios H., Bao T.T., Pasic M.D., Honey R.J., Stewart R., Pace K.T., Bjarnason G.A., Jewett M.A., Yousef G.M. Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses. Tumour Biol. 2012, 33:131-140.
176. Wu X., Weng L., Li X., Guo C., Pal S.K., Jin J.M., Li Y., Nelson R.A., Mu B., Onami S.H., Wu J.J., Ruel N.H., Wilczynski S.P., Gao H., Covarrubias M., Figlin R.A., Weiss L.M., Wu H. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS ONE 2012, 7:e35661.
177. Slaby O., Redova M., Poprach A., Nekvindova J., Iliev R., Radova L., Lakomy R., Svoboda M., Vyzula R. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosom. Cancer 2012, 51:707-716.
178. Slaby O., Jancovicova J., Lakomy R., Svoboda M., Poprach A., Fabian P., Kren L., Michalek J., Vyzula R. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J. Exp. Clin. Cancer Res. 2010, 29:90.
179. Wotschofsky Z., Busch J., Jung M., Kempkensteffen C., Weikert S., Schaser K.D., Melcher I., Kilic E., Miller K., Kristiansen G., Erbersdobler A., Jung K. Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clin. Chim. Acta 2012.
180. H. Faragalla, Y.M. Youssef, A. Scorilas, B. Khalil, N.M. White, S. Mejia-Guerrero, H. Khella, M.A. Jewett, A. Evans, Z. Lichner, G. Bjarnason, L. Sugar, M.I. Attalah, G.M. Yousef, The Clinical Utility of miR-21 as a Diagnostic and Prognostic Marker for Renal Cell Carcinoma, J. Mol. Diagn. (2012).
181. Breault J.E., Shiina H., Igawa M., Ribeiro-Filho L.A., Deguchi M., Enokida H., Urakami S., Terashima M., Nakagawa M., Kane C.J., Carroll P.R., Dahiya R. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin. Cancer Res. 2005, 11:557-564.
182. Awakura Y., Nakamura E., Ito N., Kamoto T., Ogawa O. Methylation-associated silencing of TU3A in human cancers. Int. J. Oncol. 2008, 33:893-899.
183. Hirata H., Hinoda Y., Nakajima K., Kawamoto K., Kikuno N., Kawakami K., Yamamura S., Ueno K., Majid S., Saini S., Ishii N., Dahiya R. Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin. Cancer Res. 2009, 15:5678-5687.
184. Peters I., Eggers H., Atschekzei F., Hennenlotter J., Waalkes S., Trankenschuh W., Grosshennig A., Merseburger A.S., Stenzl A., Kuczyk M.A., Serth J. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression. BJU Int. 2012, 110:E144-E152.
185. Ahmad S.T., Arjumand W., Seth A., Saini A.K., Sultana S. Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population. Tumour Biol. 2012, 33:395-402.
186. Christoph F., Kempkensteffen C., Weikert S., Kollermann J., Krause H., Miller K., Schostak M., Schrader M. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br. J. Cancer 2006, 95:1701-1707.
187. Hirata H., Hinoda Y., Nakajima K., Kawamoto K., Kikuno N., Ueno K., Yamamura S., Zaman M.S., Khatri G., Chen Y., Saini S., Majid S., Deng G., Ishii N., Dahiya R. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int. J. Cancer 2010, 128:1793-1803.
188. Zhang Q., Ying J., Li J., Fan Y., Poon F.F., Ng K.M., Tao Q., Jin J. Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage. J. Urol. 2010, 184:731-737.
189. van Vlodrop I.J., Baldewijns M.M., Smits K.M., Schouten L.J., van Neste L., van Criekinge W., van Poppel H., Lerut E., Schuebel K.E., Ahuja N., Herman J.G., de Bruine A.P., van Engeland M. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am. J. Pathol. 2010, 176:575-584.
190. Yoo K.H., Park Y.K., Kim H.S., Jung W.W., Chang S.G. Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma. Pathol. Int. 2010, 60:661-666.
191. Gonzalgo M.L., Yegnasubramanian S., Yan G., Rogers C.G., Nicol T.L., Nelson W.G., Pavlovich C.P. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin. Cancer Res. 2004, 10:7276-7283.
192. Kawai Y., Sakano S., Suehiro Y., Okada T., Korenaga Y., Hara T., Naito K., Matsuyama H., Hinoda Y. Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma. Ann. Oncol. 2010, 21:1612-1617.
193. Hildebrandt M.A., Gu J., Lin J., Ye Y., Tan W., Tamboli P., Wood C.G., Wu X. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010, 29:5724-5728.